Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
about
Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis.Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts.Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancerReview: cancer-induced autoimmunity in the rheumatic diseases.Cancer risk in dermatomyositis: a meta-analysis of cohort studies.Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle.Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.Myositis autoantibodies and clinical phenotypes.Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease.Analysis of the SUMO2 Proteome during HSV-1 Infection.Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease.PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.Polymyositis and dermatomyositis as a risk of developing cancer.Association of Antibodies to Interferon-Inducible Protein-16 With Markers of More Severe Disease in Primary Sjögren's Syndrome.The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomesFrom pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link.Multivalent Chromatin Engagement and Inter-domain Crosstalk Regulate MORC3 ATPase.Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.Regional ischemic immune myopathy: a paraneoplastic dermatomyopathy.Idiopathic inflammatory myopathies-a review.A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.The Clinical Features of Myositis-Associated Autoantibodies: a Review.Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort.Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.Malignancy screening in autoimmune myositis amongst Australian Rheumatologists.Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin.Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients.Integrated classification of inflammatory myopathies.Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature.Pharmacological management of dermatomyositis.Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis.High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody.NXP-2 Positive Dermatomyositis: A Unique Clinical Presentation.
P2860
Q30252086-90105FD6-3F35-4C1A-A503-F062CCA953B8Q33592767-6A8EDA8C-11AB-4CCB-A628-DC11ACD5CB07Q33670102-7876A8AD-B46F-4D38-825F-3E69CF3FA412Q33812271-04F351C9-E003-4BF4-8133-EF7F5AC4CB96Q34666066-7C989334-BEBE-4638-81AB-63A315F55A94Q34668158-F676FD4A-67B0-4B25-8F2B-DE744BA1A1CDQ34791339-FB11D1B2-8603-4A40-B3E8-20B56AADA87AQ35153832-AAF3742B-70C9-47B6-9278-0EFA13381CCDQ35153899-CA77060E-E648-4CF6-9C4D-1D9E5251DA1FQ35281962-8A72F778-DDDB-4A5D-8EB4-ADF3287E4CC6Q35454043-A303B04C-368C-47A6-856C-3FE54663E255Q35498937-4F7575E6-1E1C-4F12-BAE6-2175991A6C80Q35705640-6E4BDB67-F6D8-4A11-BAB8-88A1251DAEC2Q36113525-8D25A029-7329-4821-9212-14FD0F6ABADDQ36364785-D5E1152D-EE74-4FF4-8440-338FB4833A14Q36788809-5EB08655-76DB-4BD1-B110-E10FB0F86E2CQ36842357-777E3CE8-2500-458E-AD36-693762EA244FQ36842737-67C9A76F-9317-4574-8788-57E16DC9A74AQ37022721-C7BC1483-0921-400D-9701-A03E17CB9A02Q37038527-B6EDC4D2-73A6-4984-BF68-23878516AB40Q37100264-58E3CCE2-957C-4063-8B3E-CDC284A171FAQ37358050-83D0ADEF-80C7-4E0D-9F68-CF523B3AB37EQ37368405-49008C68-255F-4DDA-974D-9C01D0E4D5C1Q38266506-53D2BD8A-E567-4A15-B805-9024F9DE5AA8Q38355216-D7C757A5-B37B-4BDD-BF47-10401386BFE7Q38596370-D4BD25E5-0D95-4572-B2B4-6E423246C1EEQ38603422-995AAEB6-6A18-4A79-AD38-E9A750731DDDQ38613540-36EA4782-E99C-4F69-883F-2F8EB16272F3Q38646384-57AFA645-2321-4969-98D8-C9A5B5EB0795Q38662460-738ED23A-7099-4F01-8A31-518BE3B93A25Q38879035-AD148266-ADC7-40A6-9590-C70D0B3268EBQ38952138-C98B7FCB-D5C4-4ADD-951A-C3467AA72B7BQ38995102-03BC50C7-F102-421F-A551-3FA3D5EEE91BQ39027323-C89A6EDE-0DD9-41C7-8362-435CD7B177EBQ39044741-A6B9C697-FE6C-4CEB-AA2D-21599DF8C40BQ39425296-81D0F84D-2B6F-407F-9B87-091DE7893402Q39824090-F13A9F1F-D93B-4FC6-8677-EB087EE809DEQ40725508-157DF4E1-AD97-415F-B330-58F93D0EA07CQ40795767-4D486F05-5E7F-45F4-95F2-EF27360F7C4DQ41038527-9B10F5A5-5AA6-43BF-9D0F-98A560B11875
P2860
Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Most patients with cancer-asso ...... iption intermediary factor 1γ.
@ast
Most patients with cancer-asso ...... iption intermediary factor 1γ.
@en
type
label
Most patients with cancer-asso ...... iption intermediary factor 1γ.
@ast
Most patients with cancer-asso ...... iption intermediary factor 1γ.
@en
prefLabel
Most patients with cancer-asso ...... iption intermediary factor 1γ.
@ast
Most patients with cancer-asso ...... iption intermediary factor 1γ.
@en
P2093
P2860
P356
P1476
Most patients with cancer-asso ...... iption intermediary factor 1γ.
@en
P2093
Andrew L Mammen
Antony Rosen
David F Fiorentino
Lisa Christopher-Stine
Livia Casciola-Rosen
Lorinda S Chung
Shufeng Li
P2860
P304
P356
10.1002/ART.38093
P577
2013-11-01T00:00:00Z